Clinical Commander

Back to dossier
pulm.empyema.v1PRODUCTION
pulm.empyema.v1

Pleural Infection / Empyema

pulmonologyacutesubacuteadult
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm a pleural collection complicating pneumonia / sepsis (vs simple effusion, consolidation, abscess) on CXR/US and set acuity — acute parapneumonic vs subacute organising empyema

Inputs
2
Actions
0
Advance rule
Set
Advance when

Pleural collection complicating infection confirmed by imaging

Patient inputs (21)

RAPID age term (≥70 highest-risk) + mortality pretest (Rahman Chest 2014 PMID 24264558)

Persistent fever despite antibiotics is the cardinal pleural-infection trigger (BTS 2023)

Hypoxia → respiratory-failure severity + ICU disposition (BTS 2023)

Tachypnea + work-of-breathing severity (BTS 2023)

Septic-shock screen from empyema source (SSC 2026)

Community (Strep anginosus/milleri + anaerobes) vs hospital/post-surgical (Staph/MRSA/GNB) drives empiric antibiotic axis (BTS 2023)

Intrapleural tPA contraindicated with active intrapleural haemorrhage / recent thoracic-surgery bleeding risk / coagulopathy (MIST2 Rahman NEJM 2011 PMID 21830966)

pH <7.20 → complicated parapneumonic = drainage decision; highest-accuracy chemistry test (Heffner 1995 PMID 7767510, ROC AUC 0.92); collect anaerobically in heparinised ABG syringe on ice

Positive Gram stain / culture (or frank pus) = empyema → drainage regardless of pH; also de-escalation target (BTS 2023)

Bedside loculation/septation characterisation + always US-guided thoracentesis/drain (BTS 2023)

Initial confirmation + serial post-drain CXR (BTS 2023)

Split-pleura sign, loculation, pleural enhancement, organising rind, lung abscess vs empyema, malignant features (BTS 2023)

Aspiration → obligatory anaerobic cover; route to pulm.aspiration-pneumonia.core.v1 (BTS 2023)

Broaden empiric + atypical/fungal threshold; route to id.sepsis.core.v1 (BTS 2023)

Pleural glucose <60 mg/dL (or pleural/serum <0.5) supports complicated parapneumonic drainage when pH unavailable (Heffner 1995 PMID 7767510; ACCP Colice 2000 PMID 11035692)

Pleural LDH >1000 IU/L marks complicated parapneumonic (Light class); rising LDH = progression (BTS 2023; Heffner 1995 PMID 7767510)

Bacteraemia in ~12-14% pleural infection; microbiology de-escalation + sepsis source (BTS 2023)

CRP trend tracks treatment response in pleural infection (BTS 2023)

Sepsis severity from empyema source (SSC 2026)

RAPID renal term (urea >5 mmol/L scores) (Rahman Chest 2014 PMID 24264558)

RAPID dietary term (albumin <27 g/L scores) + nutrition status (Rahman Chest 2014 PMID 24264558; PILOT Corcoran 2020 PMID 32675200)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (7)

7 need judgement
  • informationallife_threateningseptic_shock_from_empyema
    Pleural infection with septic shock (vasopressor requirement) or organ dysfunction (Sepsis-3)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningbronchopleural_fistula
    Continuous air leak with purulent drainage (bronchopleural fistula complicating empyema)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereempyema_or_complicated_parapneumonic_drainage_threshold
    Frank pus on aspirate OR pleural pH <7.20 OR pleural glucose <60 mg/dL OR positive Gram stain/culture OR loculation on US/CT
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverefailed_medical_therapy_to_surgery
    Persistent sepsis or undrained collection despite chest tube + intrapleural tPA/DNase at 5-7 days, OR organising visceral rind trapping lung
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepleural_infection_high_rapid_risk
    RAPID score high-risk band (5-7) — 3-month mortality 29.3% (PILOT Corcoran 2020 PMID 32675200)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehospital_or_post_surgical_acquisition_resistance_risk
    Hospital-acquired, post-surgical, or post-instrumentation empyema (Staph/MRSA/Gram-negative incl. Pseudomonas)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateintrapleural_fibrinolytic_bleeding_contraindication
    Active intrapleural haemorrhage, recent thoracic surgery with bleeding risk, or significant coagulopathy in a patient who would otherwise receive intrapleural tPA/DNase
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives severity classification
Loading…

Recommended regimen

BTS 2023 + MIST2 + ACCP — parapneumonic staging, acquisition-route antibiotics, drainage ladder
axis: pleural_infection_staging_drainage_and_antibioticsstep simple_parapneumonic - Simple parapneumonic effusion — antibiotics alone, no drainage
Selected step "Simple parapneumonic effusion — antibiotics alone, no drainage" — Free-flowing small/moderate effusion, pleural pH ≥7.20, glucose ≥60 mg/dL, LDH <1000 IU/L, Gram stain + culture negative, no pus, no loculation (ACCP category 1-2; Colice 2000 PMID 11035692)
  • ampicillin-sulbactam
    first line
    aminopenicillin_BLI
    3 g IV q6h • IV • q6h (treat source pneumonia; reassess effusion 24-48 h)
    triggers: community_acquired
    Treat antecedent pneumonia + obligatory anaerobic cover should the effusion progress (BTS 2023; route to pulm.cap.core.v1)
    rxcui 1009148
  • ceftriaxone
    first line
    cephalosporin_3rd
    CTX 2 g IV q24h + metronidazole 500 mg IV q8h • IV • CTX q24h + metronidazole q8h
    triggers: penicillin_intolerance
    Alternative community regimen; metronidazole supplies the obligatory anaerobic cover (BTS 2023)
    rxcui 2193

ed playbook — drug actions (4)

  1. 1. oxygen
    2-6 L/min NC titrated • inhaled • continuous
    trigger: SpO2 <92%
    Supportive (BTS 2023)
  2. 2. empiric antibiotics — community
    Ampicillin-sulbactam 3 g IV q6h OR ceftriaxone 2 g IV q24h + metronidazole 500 mg IV q8h • IV • q6h / q24h
    trigger: Community-acquired pleural infection
    Strep anginosus/milleri + oral anaerobes; anaerobic cover obligatory (BTS 2023)
  3. 3. empiric antibiotics — hospital/post-surgical/immunocompromised
    Piperacillin-tazobactam 4.5 g IV q6h ± vancomycin 15-20 mg/kg IV LD • IV • q6h / q8-12h
    trigger: Hospital-acquired / post-surgical / immunocompromised
    Antipseudomonal + anaerobic + MRSA cover (BTS 2023)
  4. 4. acetaminophen
    1 g IV/PO q6h • IV/PO • q6h scheduled
    trigger: Pleuritic / tube pain + fever
    Multimodal analgesia + antipyresis (BTS 2023)

Auto-drafted A&P note

ed

Subjective

- Possible entry pathways: Pneumonia with persistent/recrudescent fever or failure to improve on antibiotics + new/enlarging effusion (BTS 2023 Roberts PMID 37553157); Pleural effusion / loculated collection complicating pneumonia on CXR / lung ultrasound / CT (BTS 2023); Frank pus on aspiration, pleural pH <7.20, or positive pleural Gram stain/culture (BTS 2023; Heffner 1995 PMID 7767510).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Pleural Infection / Empyema** (pulm.empyema.v1).
Phenotype framing: Bayesian fork: SIMPLE (pH ≥7.2, glucose ≥60, Gram/culture neg, free-flowing, small) → antibiotics alone; COMPLICATED (pH <7.20 OR glucose <60 OR LDH >1000 OR loculation) → drain; EMPYEMA (frank pus OR +Gram/culture) → drain. Look-alike pivots: malignant (cytology, chronicity), TB (lymphocyte-predominant, ADA >40), haemothorax (Hct >50% serum), chylothorax (triglyceride >110), lung abscess vs empyema (split-pleura sign on CT)
Scope: Confirm a pleural collection complicating pneumonia / sepsis (vs simple effusion, consolidation, abscess) on CXR/US and set acuity — acute parapneumonic vs subacute organising empyema

No severity triggers fired against current inputs.

Plan

Regimen axis: **BTS 2023 + MIST2 + ACCP — parapneumonic staging, acquisition-route antibiotics, drainage ladder** — step "Simple parapneumonic effusion — antibiotics alone, no drainage".
1. ampicillin-sulbactam 3 g IV q6h IV q6h (treat source pneumonia; reassess effusion 24-48 h) (aminopenicillin_BLI, first line) — Treat antecedent pneumonia + obligatory anaerobic cover should the effusion progress (BTS 2023; route to pulm.cap.core.v1)
2. ceftriaxone CTX 2 g IV q24h + metronidazole 500 mg IV q8h IV CTX q24h + metronidazole q8h (cephalosporin_3rd, first line) — Alternative community regimen; metronidazole supplies the obligatory anaerobic cover (BTS 2023)

Setting playbook (ed) — Recognise pleural infection complicating pneumonia/sepsis, perform US-guided diagnostic thoracentesis, stage simple-vs-complicated-vs-empyema, start empiric antibiotics by acquisition route, drain pus, admit
3. oxygen 2-6 L/min NC titrated inhaled continuous — SpO2 <92% (Supportive (BTS 2023))
4. empiric antibiotics — community Ampicillin-sulbactam 3 g IV q6h OR ceftriaxone 2 g IV q24h + metronidazole 500 mg IV q8h IV q6h / q24h — Community-acquired pleural infection (Strep anginosus/milleri + oral anaerobes; anaerobic cover obligatory (BTS 2023))
5. empiric antibiotics — hospital/post-surgical/immunocompromised Piperacillin-tazobactam 4.5 g IV q6h ± vancomycin 15-20 mg/kg IV LD IV q6h / q8-12h — Hospital-acquired / post-surgical / immunocompromised (Antipseudomonal + anaerobic + MRSA cover (BTS 2023))
6. acetaminophen 1 g IV/PO q6h IV/PO q6h scheduled — Pleuritic / tube pain + fever (Multimodal analgesia + antipyresis (BTS 2023))

Non-pharmacologic actions:
- US-guided diagnostic thoracentesis; aspirate frank pus = empyema regardless of chemistry (BTS 2023)
- Small-bore (10-14F) chest tube if pus / pH <7.20 / positive Gram stain / loculation — small-bore acceptable (BTS 2023)
- CT chest with contrast if loculation / organising rind / lung-abscess-vs-empyema question (BTS 2023)
- Sepsis bundle + source control if septic shock from empyema (SSC 2026)

AVOID / contraindication checks:
- Intrapleural_tPA_DNase_avoid_if_active_intrapleural_haemorrhage_or_recent_thoracic_surgery_or_coagulopathy (MIST2 Rahman NEJM 2011 PMID 21830966)
- Never_give_intrapleural_DNase_without_tPA_monotherapy_ineffective_and_DNase_alone_harmful_OR_3.56 (MIST2 PMID 21830966)
- Intrapleural_streptokinase_not_recommended_no_benefit (MIST1 Maskell NEJM 2005 PMID 15745977)
- Anaerobic_coverage_obligatory_in_community_and_aspiration_pleural_infection (BTS 2023)
- Vancomycin_piptazo_meropenem_renal_dose_adjust_per_eGFR (KDIGO 2024)
- Metronidazole_hepatic_caution_in_cirrhosis (BTS 2023)
- Thoracentesis_drain_always_ultrasound_guided (BTS 2023)
- Prolonged_antibiotic_course_2_to_6_weeks_do_not_truncate_at_standard_pneumonia_duration (BTS 2023)

Monitoring

Regimen monitoring:
- serial chest-tube output + patency (BTS 2023)
- daily post-tube CXR (BTS 2023)
- CRP + fever curve trend (BTS 2023)
- repeat lung ultrasound for residual loculation (BTS 2023)
- pleural-space bleeding watch during tPA/DNase course (MIST2 PMID 21830966)
- microbiology for antibiotic de-escalation (BTS 2023)
- renal function for vancomycin/pip-tazo/meropenem dosing (KDIGO 2024)
- albumin / nutrition trend (PILOT Corcoran 2020 PMID 32675200)

Setting (ed) monitoring:
- Vitals + post-procedure CXR (iatrogenic pneumothorax) (BTS 2023)
- Lactate + sepsis markers if septic (SSC 2026)

Follow-up plan: Complete prolonged antibiotic course (2-6 weeks; longer for organising empyema), follow-up imaging to radiographic resolution, nutritional rehabilitation, source-pneumonia / aspiration-risk workup, return-to-work counselling (~4 wk; Meggyesy 2024 PMID 39037060)
- Close-out criterion: Antibiotic plan + imaging follow-up + nutrition plan scheduled

Monitoring phase: Drain output + patency, daily post-tube CXR, CRP/fever curve, repeat US for residual loculation, pleural-space bleeding watch during tPA/DNase course, microbiology for de-escalation

Disposition

Current setting: ed — Recognise pleural infection complicating pneumonia/sepsis, perform US-guided diagnostic thoracentesis, stage simple-vs-complicated-vs-empyema, start empiric antibiotics by acquisition route, drain pus, admit

Disposition criteria:
- Admit ward: complicated parapneumonic / empyema requiring chest tube + IV antibiotics (BTS 2023)
- Admit ICU: septic shock, respiratory failure, BPF (BTS 2023; SSC 2026)
- Simple parapneumonic with stable source pneumonia: admit for antibiotics + 24-48 h effusion reassessment (rarely outpatient) (BTS 2023)

Escalation triggers (move to higher acuity):
- Septic shock from empyema → SSC 2026 bundle + ICU + emergent drainage
- Bronchopleural fistula (continuous air leak + pus) → thoracic surgery
- Hypoxic respiratory failure from large infected effusion → ICU

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Pleural infection with septic shock (vasopressor requirement) or organ dysfunction (Sepsis-3)
- [LIFE_THREATENING] Continuous air leak with purulent drainage (bronchopleural fistula complicating empyema)
- [SEVERE] Frank pus on aspirate OR pleural pH <7.20 OR pleural glucose <60 mg/dL OR positive Gram stain/culture OR loculation on US/CT

Citations

- BTS 2023 Guideline for Pleural Disease (Roberts, Thorax 2023) — pleural infection; with MIST2 (intrapleural tPA+DNase), MIST1 (streptokinase null), RAPID/PILOT (mortality risk), Heffner pH meta-analysis, ACCP parapneumonic guideline [PMID:37553157](https://pubmed.ncbi.nlm.nih.gov/37553157/)
- Cited evidence (PMID 37433578) [PMID:37433578](https://pubmed.ncbi.nlm.nih.gov/37433578/)
- Cited evidence (PMID 21830966) [PMID:21830966](https://pubmed.ncbi.nlm.nih.gov/21830966/)
- Cited evidence (PMID 15745977) [PMID:15745977](https://pubmed.ncbi.nlm.nih.gov/15745977/)
- Cited evidence (PMID 24264558) [PMID:24264558](https://pubmed.ncbi.nlm.nih.gov/24264558/)

Last reconciled with current guidelines: 2026-05-16.
References
  • BTS 2023 Guideline for Pleural Disease (Roberts, Thorax 2023) — pleural infection; with MIST2 (intrapleural tPA+DNase), MIST1 (streptokinase null), RAPID/PILOT (mortality risk), Heffner pH meta-analysis, ACCP parapneumonic guideline — PMID:37553157
  • Cited evidence (PMID 37433578) — PMID:37433578
  • Cited evidence (PMID 21830966) — PMID:21830966
  • Cited evidence (PMID 15745977) — PMID:15745977
  • Cited evidence (PMID 24264558) — PMID:24264558